Hematologic Malignancy
Myeloid Leukemia
CI-CAN-00001251Explore in graph →
Hematologic862 active trials22 approved drugs599 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00001251Explore in graph →
Clinical trials
3,528 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (617)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00407966 | Alvocidib, Cytarabine, and Mitoxantrone in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia | completed | Phase 2 | 45 | National Cancer Institute (NCI)NIH | 1 | Aug 4, 2015 | clinicaltrials |
| NCT02511340 | A Phase II Study to Evaluate the Efficacy and the Safety of Flumatinib in CML-AP or CML-BP Patients | unknown | Phase 2 | 167 | Jiangsu Hansoh Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jul 30, 2015 | clinicaltrials |
| NCT00878722 | Trial of PXD101 (Belinostat) in Combination With Idarubicin to Treat AML Not Suitable for Standard Intensive Therapy | completed | Phase 1 / Phase 2 | 41 | Valerio TherapeuticsINDUSTRY | 3 | Jul 28, 2015 | clinicaltrials |
| NCT00565058 | Combination of GTI-2040 and Cytarabine in the Treatment of Refractory and Relapsed Acute Myeloid Leukemia (AML) | completed | Phase 2 | 27 | Aptose Biosciences Inc.INDUSTRY | 1 | Jul 27, 2015 | clinicaltrials |
| NCT00533078 | Lipid Use, Nutrition, and Colitis in Patients With Hematological Malignancies(LUNCH1) | completed | Phase 2 | 14 | Insel Gruppe AG, University Hospital BernOTHER | 1 | Jul 23, 2015 | clinicaltrials |
| NCT00469729 | Efficacy and Safety Study of StemEx®, to Treat Subjects With High Risk Hematologic Malignancies, Following Myeloablative Therapy(ExCell) | completed | Phase 2 / Phase 3 | 101 | Gamida Cell -Teva Joint Venture Ltd.OTHER | 5 | Jul 10, 2015 | clinicaltrials |
| NCT00634244 | Comparing Three Different Combination Chemotherapy Regimens in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia | completed | Phase 2 | 92 | National Cancer Institute (NCI)NIH | 2 | Jul 7, 2015 | clinicaltrials |
| NCT02261779 | Phase I/II Trial of ATRA and TCP in Patients With Relapsed or Refractory AML and no Intensive Treatment is Possible(TCP-AML) | unknown | Phase 1 / Phase 2 | 16 | Martin-Luther-Universität Halle-WittenbergOTHER | 1 | Jul 7, 2015 | clinicaltrials |
| NCT00324220 | A Phase I/II Study of MGCD0103 With Azacitidine in Patients With High-Risk Myelodysplastic Syndrome (MDS) or Acute Myelogenous Leukemia | completed | Phase 1 / Phase 2 | 66 | Mirati Therapeutics Inc.INDUSTRY | 1 | Jul 1, 2015 | clinicaltrials |
| NCT00374296 | MGCD0103 in Elderly Patients With Previously Untreated AML/High Risk MDS or Adults With Relapsed/Refractory Disease | terminated | Phase 2 | 35 | Mirati Therapeutics Inc.INDUSTRY | 2 | Jul 1, 2015 | clinicaltrials |
| NCT00954941 | Ondansetron Versus Aprepitant Plus Ondansetron for Emesis | completed | Phase 2 | 100 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 25, 2015 | clinicaltrials |
| NCT00175812 | Differentiation Induction in Acute Myelogenous Leukemia | completed | Phase 1 / Phase 2 | 24 | University of BergenOTHER | 1 | Jun 24, 2015 | clinicaltrials |
| NCT00995332 | Disease Stabilization in AML by Treatment With ATRA, Valproic Acid and Low-dose Cytarabine | completed | Phase 1 / Phase 2 | 36 | University of BergenOTHER | 1 | Jun 24, 2015 | clinicaltrials |
| NCT01369368 | Treatment of Acute Leukemia Relapse After Allotransplantation | unknown | Phase 1 / Phase 2 | 20 | University of BergenOTHER | 1 | Jun 24, 2015 | clinicaltrials |
| NCT01222143 | Safety and Efficacy Study of Nilotinib Combined With Mitoxantrone, Etoposide, and High-dose Cytarabine Induction Chemotherapy Followed by Consolidation for Patients With C-kit Positive Acute Myeloid Leukemia | terminated | Phase 1 / Phase 2 | 12 | University Health Network, TorontoOTHER | 1 | Jun 22, 2015 | clinicaltrials |
| NCT00957385 | Maintenance Therapy in Acute Myeloid Leukemia (AML) Patients | completed | Phase 2 | 24 | University Health Network, TorontoOTHER | 1 | Jun 19, 2015 | clinicaltrials |
| NCT01521936 | Cholecalciferol in Treating Patients With Acute Myeloid Leukemia Undergoing Intensive Induction Chemotherapy | terminated | Phase 2 | 4 | Roswell Park Cancer InstituteOTHER | 1 | Jun 19, 2015 | clinicaltrials |
| NCT00034684 | Study of Farnesyl Protein Transferase Inhibitor (FPTI) in Patients With Leukemia (Study P00701) | completed | Phase 1 / Phase 2 | 132 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Jun 17, 2015 | clinicaltrials |
| NCT01188889 | RAD001 in Patients With Chronic Phase Chronic Myeloid Leukemia w/ Molecular Disease. | withdrawn | Phase 1 / Phase 2 | 0 | University of Michigan Rogel Cancer CenterOTHER | 1 | May 15, 2015 | clinicaltrials |
| NCT00666497 | Phase 2 Study of Azacitidine (Vidaza) vs MGCD0103 vs Combination in Elderly Subjects With Newly Diagnosed Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) | terminated | Phase 2 | 6 | Mirati Therapeutics Inc.INDUSTRY | 3 | May 8, 2015 | clinicaltrials |
| NCT00885508 | A Study of the Efficacy and Safety of Lenalidomide Combined to Escalating Doses of Chemotherapy in Intermediate-2-or High Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) With Del 5q(GFM-Chimio-Rev) | unknown | Phase 2 | 85 | Groupe Francophone des MyelodysplasiesOTHER | 1 | Apr 24, 2015 | clinicaltrials |
| NCT01361464 | Tipifarnib in Treating Older Patients With Acute Myeloid Leukemia | completed | Phase 2 | 21 | National Cancer Institute (NCI)NIH | 1 | Apr 8, 2015 | clinicaltrials |
| NCT00924443 | A Study of Clofarabine in Older Patients With Acute Myeloid Leukemia (AML) for Whom Chemotherapy Is Not Suitable | completed | Phase 2 | 69 | Genzyme, a Sanofi CompanyINDUSTRY | 3 | Apr 1, 2015 | clinicaltrials |
| NCT00098033 | Investigation of Clofarabine in Acute Leukemias | completed | Phase 2 | 64 | University of TexasOTHER | 0 | Mar 25, 2015 | clinicaltrials |
| NCT01819558 | Phase I/II Study of Immune Therapy After Allograft in Patients With Myeloid Hemopathy(ALLO-WT1) | completed | Phase 1 / Phase 2 | 2 | Institut Paoli-CalmettesOTHER | 1 | Mar 20, 2015 | clinicaltrials |
| NCT00656617 | Phase II Study of Idarubicin, Cytarabine, and Vorinostat With High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) | completed | Phase 2 | 106 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 9, 2015 | clinicaltrials |
| NCT01010373 | Safety and Efficacy Study of AS101 to Treat Elderly Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Patients | suspended | Phase 2 | 12 | BioMAS LtdINDUSTRY | 1 | Feb 10, 2015 | clinicaltrials |
| NCT00114959 | Homoharringtonine With Oral Gleevec in Chronic, Accelerated and Blast Phase Chronic Myeloid Leukemia (CML) | terminated | Phase 2 | 15 | ChemGenex PharmaceuticalsINDUSTRY | 1 | Jan 15, 2015 | clinicaltrials |
| NCT00528333 | A Study of Lintuzumab (SGN-33) in Combination With Low Dose Cytarabine in Patients 60+ Years With AML | completed | Phase 2 | 211 | Seagen Inc.INDUSTRY | 1 | Jan 7, 2015 | clinicaltrials |
| NCT00381550 | 3-AP and Fludarabine in Treating Patients With Myeloproliferative Disorders, Chronic Myelomonocytic Leukemia, or Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia | completed | Phase 2 | 35 | National Cancer Institute (NCI)NIH | 1 | Jan 6, 2015 | clinicaltrials |
| NCT02275663 | Azacytidine Plus FLAG for Relapsed or Refractory AML | unknown | Phase 2 | 37 | King Fahad Medical CityOTHER_GOV | 1 | Jan 6, 2015 | clinicaltrials |
| NCT00661180 | Open Label Phase II Study of BAY 43-9006 in Chronic Myelogenous Leukemia (CML) Patients Resistant to Gleevec(ORACLE) | completed | Phase 2 | 10 | BayerINDUSTRY | 2 | Dec 23, 2014 | clinicaltrials |
| NCT00858806 | Intermittent Imatinib Treatment in Chronic Myeloid Leukemia and Philadelphia Chromosome (Ph+CML) Patients Who Achieved a Complete Cytogenetic Response (CCgR) on Standard Imatinib Therapy(INTERIM0407) | completed | Phase 2 | 78 | Università degli Studi di BresciaOTHER | 1 | Dec 3, 2014 | clinicaltrials |
| NCT00907582 | ASCT for Relapsed APL After Molecular Remission | terminated | Phase 2 | 5 | Shanghai Jiao Tong University School of MedicineOTHER | 1 | Dec 2, 2014 | clinicaltrials |
| NCT00602771 | Tipifarnib and Etoposide in Treating Older Patients With Newly Diagnosed, Previously Untreated Acute Myeloid Leukemia | completed | Phase 2 | 84 | National Cancer Institute (NCI)NIH | 1 | Oct 9, 2014 | clinicaltrials |
| NCT00074737 | Dosing Study of Ara-C/EL625/Idarubicin in Refractory and Relapsed AML | completed | Phase 2 | 53 | Eleos, Inc.INDUSTRY | 1 | Sep 18, 2014 | clinicaltrials |
| NCT00967512 | Aezea® (Cenersen) and Chemotherapy for AML Subjects ≥ 55 Years of Age With No Response to Frontline Induction Course | withdrawn | Phase 2 | 0 | Eleos, Inc.INDUSTRY | 0 | Sep 18, 2014 | clinicaltrials |
| NCT00593645 | Clofarabine, Cytarabine, and Thymoglobulin for Allogeneic Transplantation | terminated | Phase 2 | 7 | Washington University School of MedicineOTHER | 1 | Sep 12, 2014 | clinicaltrials |
| NCT00742625 | Bortezomib, Daunorubicin, and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia | completed | Phase 1 / Phase 2 | 95 | National Cancer Institute (NCI)NIH | 1 | Sep 12, 2014 | clinicaltrials |
| NCT00184054 | Trial of Arsenic Trioxide With Ascorbic Acid in the Treatment of Adult Non-Acute Promyelocytic Leukemia (APL) Acute Myelogenous Leukemia | terminated | Phase 2 | 11 | University of Southern CaliforniaOTHER | 1 | Jul 25, 2014 | clinicaltrials |
| NCT00433745 | Wilm's Tumor 1 (WT1) Peptide Vaccine for High Risk Hematologic Malignancy | completed | Phase 2 | 4 | National Heart, Lung, and Blood Institute (NHLBI)NIH | 1 | Jul 8, 2014 | clinicaltrials |
| NCT02182596 | DNR and AraC Combined to Fractionated Mylotarg® in Patients With First Relapse of AML(MYLOFRANCE2) | completed | Phase 1 / Phase 2 | 20 | Acute Leukemia French AssociationOTHER | 1 | Jul 8, 2014 | clinicaltrials |
| NCT00415909 | TALL-104 and Gleevec in Chronic Myelogenous Leukemia Patients | terminated | Phase 2 | 3 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 30, 2014 | clinicaltrials |
| NCT02103322 | Comparative Bioequivalence Study in Adult Patients Suffering From Chronic Myeloid Leukemia & Gastrointestinal Stromal Tumor Under Fed Conditions | completed | Phase 2 / Phase 3 | 48 | Amneal Pharmaceuticals, LLCINDUSTRY | 1 | Jun 27, 2014 | clinicaltrials |
| NCT01236144 | A Trial to Establish the Feasibility of Combining Either the Tyrosine Kinase Inhibitor AC220,CXCR4 Inhibitor Plerixafor or HSP90 Inhibitor Ganetespib With Chemotherapy in Older Patients With Acute Myeloid Leukaemia and High Risk Myelodysplastic Syndrome.(AML18 Pilot) | completed | Phase 1 / Phase 2 | 113 | Cardiff UniversityOTHER | 1 | Jun 11, 2014 | clinicaltrials |
| NCT00387426 | Sunitinib in Treating Patients With Idiopathic Myelofibrosis | terminated | Phase 2 | 14 | National Cancer Institute (NCI)NIH | 1 | May 28, 2014 | clinicaltrials |
| NCT00096122 | Idarubicin, Cytarabine, and Tipifarnib in Treating Patients With Newly Diagnosed Myelodysplastic Syndromes or Acute Myeloid Leukemia | completed | Phase 1 / Phase 2 | 95 | National Cancer Institute (NCI)NIH | 1 | May 26, 2014 | clinicaltrials |
| NCT00305773 | Vorinostat in Treating Patients With Acute Myeloid Leukemia | completed | Phase 2 | 37 | National Cancer Institute (NCI)NIH | 1 | May 19, 2014 | clinicaltrials |
| NCT00909168 | Induction, Consolidation and Intensification Therapy for Patients Younger Than 66 Years With Previously Untreated CD33 Positive Acute Myeloid Leukemia (AML)(MYFLAI07) | completed | Phase 2 / Phase 3 | 130 | University Hospital, Udine, ItalyOTHER | 1 | May 6, 2014 | clinicaltrials |
Data updated 23 days agoSource updated Aug 4, 2015source: clinicaltrials